ERBB2 and cancer: Yonesaka et al. showed that activation of HER2 signaling in cancer cells, through either HER2 gene amplification or upregulation of the HER2/HER3 ligand heregulin, is enabled to acquire the resistance to anti-EGFR therapies [73].